EUVIMEDΑνακαλύψτε το EUVIMED
Crossref

Flavokawain A Targets CXCR4 ‐Mediated Vasculogenic Mimicry to Reverse Hepatocellular Carcinoma Resistance to Tyrosine Kinase Inhibitors

Ning Zheng, Yan Chen, Shijie Luo, Jialin Luo, Ayixuwake Bahediyaer, Shizhen Su, Lixian Wu, Jichuang Wang iD

Phytotherapy Research · 2026-07 · 40 (7) · 4206-4227

DOI: 10.1002/ptr.70360 ↗

At a glance

Journal article in Phytotherapy Research, published online on 2026-04-29. Written by Ning Zheng and 7 co-authors. Institution: Department of Pharmacology, School of Pharmacy, Fujian Key Laboratory of Natural Medicine Pharmacology, Fujian Medical University, Fuzhou, China. Major MEDLINE topics: Receptors, CXCR4, Liver Neoplasms, Carcinoma, Hepatocellular, Drug Resistance, Neoplasm. Cited 1 times so far (Crossref); 65 references. Funded by: Natural Science Foundation of Fujian Province, Joint Funds for the Innovation of Science and Technology, Fujian Province, Startup Fund for Scientific Research of High-Level Talent of Fujian Medical University.

ΠερίληψηSubjectsΒιβλιογραφικά στοιχείαCiteRelated studies

Abstract (original language)

Tyrosine kinase inhibitors (TKIs), such as sorafenib, lenvatinib, and regorafenib, serve as the mainstay targeted therapies for advanced hepatocellular carcinoma (HCC), yet resistance severely limits their clinical benefits. This study aimed to elucidate the role of CXCR4 in promoting vasculogenic mimicry (VM) to drive TKI resistance and to explore the natural chalcone flavokawain A (FKA) as a novel CXCR4‐targeting agent to overcome this challenge. Utilizing comprehensive experimental approaches—including transcriptome sequencing, MTT, transwell and 3D‐tubule formation assays, western blotting, molecular docking, cellular thermal shift assay (CETSA), and a subcutaneous xenograft model—we confirmed that sorafenib (0–8 μM) elevated CXCR4, consistent with our prior reports, and first revealed a similar upregulation occurred following exposure to lenvatinib (0–10 μM) and regorafenib (0–2 μM), with CXCR4 further enriched in TKI‐resistant cells. CXCR4 overexpression promoted VM formation and reduced TKI sensitivity, while its knockdown suppressed VM and restored TKI responsiveness. Mechanistically, CXCR4 facilitated VM through the Snail/E‐cadherin/Vimentin and VE‐cadherin/EphA2/MMP‐14/MMP‐2/Laminin5γ2 pathways. TKI‐resistant cells with upregulated CXCR4 exhibited a pronounced VM phenotype, including enhanced proliferation, migration, invasion, and VM. CXCR4 depletion attenuated these VM hallmarks and resensitized resistant cells to TKIs. FKA disrupted the VM phenotype by directly targeting CXCR4, and synergized with TKI to inhibit HCC growth in vitro and in vivo, with its efficacy being CXCR4‐dependent. Collectively, our findings suggest that CXCR4 promotes VM to drive TKI resistance and reveal that FKA, as a potential CXCR4 inhibitor, represents a promising therapeutic strategy in combination with TKIs to overcome resistance in HCC.

Subjects

MeSH terms (MEDLINE)

Receptors, CXCR4Liver NeoplasmsCarcinoma, HepatocellularDrug Resistance, NeoplasmProtein Kinase InhibitorsFlavonoidsHumansAnimalsCell Line, TumorMiceMice, NudeNeovascularization, PathologicPhenylurea CompoundsSorafenibXenograft Model Antitumor AssaysMolecular Docking SimulationMice, Inbred BALB CPyridinesQuinolines

Author keywords

CXCR4Flavokawain Adrug resistancehepatocellular carcinomatyrosine kinase inhibitorsvasculogenic mimicry

Substances

Receptors, CXCR4Protein Kinase InhibitorsCXCR4 protein, humanPhenylurea CompoundsSorafeniblenvatinibregorafenibFlavonoidsPyridinesQuinolines

Authors and institutions

  • Department of Pharmacology, School of Pharmacy, Fujian Key Laboratory of Natural Medicine Pharmacology, Fujian Medical University, Fuzhou, China.
  • Fujian Key Laboratory of Cognitive Function and Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.

ORCID profiles: Jichuang Wang

Funding

  • Natural Science Foundation of Fujian Province
  • Joint Funds for the Innovation of Science and Technology, Fujian Province
  • Startup Fund for Scientific Research of High-Level Talent of Fujian Medical University
  • Open Project of Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases

Cite

APA

Zheng, N., Chen, Y., Luo, S., Luo, J., Bahediyaer, A., Su, S., Wu, L., & Wang, J. (2026). Flavokawain A Targets CXCR4 ‐Mediated Vasculogenic Mimicry to Reverse Hepatocellular Carcinoma Resistance to Tyrosine Kinase Inhibitors. Phytotherapy Research, 40(7), 4206-4227. https://doi.org/10.1002/ptr.70360

Vancouver

Zheng N, Chen Y, Luo S, Luo J, Bahediyaer A, Su S, et al. Flavokawain A Targets CXCR4 ‐Mediated Vasculogenic Mimicry to Reverse Hepatocellular Carcinoma Resistance to Tyrosine Kinase Inhibitors. Phytotherapy Research. 2026;40(7):4206-4227. doi:10.1002/ptr.70360

BibTeX
@article{Zheng2026,
  author = {Zheng, Ning and Chen, Yan and Luo, Shijie and Luo, Jialin and Bahediyaer, Ayixuwake and Su, Shizhen and Wu, Lixian and Wang, Jichuang},
  title = {Flavokawain A Targets CXCR4 ‐Mediated Vasculogenic Mimicry to Reverse Hepatocellular Carcinoma Resistance to Tyrosine Kinase Inhibitors},
  journal = {Phytotherapy Research},
  year = {2026},
  volume = {40},
  number = {7},
  pages = {4206--4227},
  doi = {10.1002/ptr.70360}
}
Start for free →